Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Glibenclamide Combined With Rt-PA in Treating Acute Ischemic Stroke
NCT03284463Phase 3Completed
- Sponsor
- Nanfang Hospital, Southern Medical University
- Start
- Jan 2018
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in ischemic stroke comparing Glibenclamide with Placebo (2 arms). Primary endpoint: Modified Rankin Scale of 0 to 2 points at 90 days. Started Jan 2018; status: completed.
02
Drugs
glibenclamide
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT03284463.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284463.